CClinicalTrials.gg
CompletedNCT03645967Updated Jul 3, 2024Results posted

Efficacy of a Prepackaged Cleansing Cloth and Standardized Cleansing Protocol for Catheter Care at Reducing CAUTI Rates

An interventional study of ReadyCleanse Cloths in Catheter-Associated Urinary Tract Infection, sponsored by Medline Industries. Completed at 4 sites in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-07-03.

Sponsored by Medline Industries · Not applicable, Interventional, and Prevention

Phase
Not applicable
Study type
Interventional
Enrollment
9,891
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

Superiority study evaluating the efficacy of a prepackaged cleansing cloth and standardizing cleansing protocol vs. previous standard-of-care for catheter care and maintenance.

Read the detailed description

A superiority study evaluating the efficacy of a complete cleansing system composed of 5 prepackaged, moistened cloths with a standardized cleaning method compared to the previous standard-of-care for catheter care and maintenance. The primary objective is to investigate if the implementation of prepackaged cleansing cloths with a standardized cleaning protocol for all indwelling urinary catheter (IUC) care and maintenance provides a reduction in CAUTIs. The ReadyCleanse complete cleansing system will replace the previous standard-of-care. The ReadyCleanse intervention will be compared to the previous standard-of-care retrospectively.

02

Conditions studied

  • Catheter-Associated Urinary Tract Infection
03

In context

Infections

6,687 studies on the registry are indexed under Infections; 807 are open to participants now.

This study's enrollment of 9,891 is above the median of 120 across 4,201 interventional studies indexed under Infections.

Browse Infections studies →

Lead sponsor

Medline Industries is the lead sponsor of 38 studies on the registry; none are open to participants now.

Of its 15 completed or terminated interventional studies of FDA-regulated products, 14 (93%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • any adult patient who requires an IUC to be placed during admission to one of the four study hospitals

Exclusion criteria

Exclusion Criteria:

  • patients \<18 years of age
  • patients whose entire hospital stay occurs in: pediatric unit, psychiatric unit, labor \& delivery or postpartum units, and emergency room
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
9,891 participants (actual)

Study arms

  • Other
    ReadyCleanse for IUC

    ReadyCleanse Cloths will be used for the standard of care for indwelling urinary catheter care and maintenance. The old standard of care will no longer be used.

    Device: ReadyCleanse Cloths

Interventions

  • DeviceReadyCleanse Cloths

    ReadyCleanse cloths and the standardized cleansing procedure will be the standard-of-care for catheter care and maintenance; patients will undergo routine perineal care for a minimum of twice per day and after each incontinent episode.

06

What researchers measure

Primary outcomes

  1. Infections Per 1,000 (CAUTI) Days

    Incidence Rate for CAUTIs per 1,000 Catheter days

    Time frame: 16 months

Secondary outcomes

  1. Number of "Health Care Providers Responding to Health Care Provider Feedback Survey

    Healthcare provider feedback survey will be delivered to all staff that have utilized the ReadyCleanse cloths for indwelling urinary catheter care and maintenance. Purpose of the survey is to investigate healthcare provider preference and opinion of device.

    Time frame: Begins 3 months after start date. Time to take survey is approximately 10 minutes.

07

Results

Posted Jul 3, 2024

Participant flow

Participant flow — Overall Study
MilestoneReadyCleanse for IUC
Started9891
Completed9891
Not completed0

Outcome measures

PrimaryInfections Per 1,000 (CAUTI) Days

Incidence Rate for CAUTIs per 1,000 Catheter days

Time frame:
16 months
Reported as:
Number · infection per 1,000 catheter days
Infections Per 1,000 (CAUTI) Days
infection per 1,000 catheter daysReadyCleanse for IUC
Infections Per 1,000 (CAUTI) Days0.8429 (0.6080 to 1.1685)
SecondaryNumber of "Health Care Providers Responding to Health Care Provider Feedback Survey

Healthcare provider feedback survey will be delivered to all staff that have utilized the ReadyCleanse cloths for indwelling urinary catheter care and maintenance. Purpose of the survey is to investigate healthcare provider preference and opinion of device.

Time frame:
Begins 3 months after start date. Time to take survey is approximately 10 minutes.
Reported as:
Count of participants · Participants
Number of "Health Care Providers Responding to Health Care Provider Feedback Survey
ParticipantsReadyCleanse for IUC
Number of "Health Care Providers Responding to Health Care Provider Feedback Survey121

Adverse events

Collected over Participant Duration: Participant had an IUC inserted during their hospital stay, through study completion, an average of 4 days with 61 being the maximum number of days.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
ReadyCleanse for IUC0/9,872 (0%)0/9,872 (0%)0/9,872 (0%)

Baseline characteristics

Age, Continuous
Age, Continuous(years)ReadyCleanse for IUC
Mean37.1 (24 to 50)
Sex: Female, Male
Sex: Female, Male(Participants)ReadyCleanse for IUC
Female4540
Male5351
Race (NIH/OMB)
Race (NIH/OMB)(Participants)ReadyCleanse for IUC
American Indian or Alaska Native0
Asian457
Native Hawaiian or Other Pacific Islander8
Black or African American530
White7105
More than one race204
Unknown or Not Reported1587
Region of Enrollment
Region of Enrollment(participants)ReadyCleanse for IUC
United States9891
08

Study locations

4 sites
  • NorthShore University HealthSystem - Evanston
    Evanston, Illinois 60201, United States
  • NorthShore University HealthSystem - Glenbrook
    Glenview, Illinois 60026, United States
  • NorthShore University HealthSystem - Highland Park
    Highland Park, Illinois 60035, United States
  • NorthShore University HealthSystem - Skokie
    Skokie, Illinois 60076, United States
09

References and documents

Study documents

  • Protocol and statistical analysis plan · Dec 19, 2019

Documents are hosted by the registry — open the source record to download them.

Individual participant data

Plan to share: No

10

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 3, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03645967
Lead sponsor
Medline Industries
Responsible party
Sponsor
First posted
Aug 24, 2018
Start date
Aug 1, 2018
Primary completion
Feb 26, 2021
Completion
Feb 26, 2021
Results posted
Jul 3, 2024
Last update
Jul 3, 2024

Study contacts

Kamal S Singh, MD
principal investigator · Endeavor Health

Oversight

FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion